Ngā hua rapu - Ursula A. Matulonis

Whakamahine hua
  1. 1
    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential mā Tarra Evans, Ursula A. Matulonis

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? mā Ursula A. Matulonis, Bradley J. Monk

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies mā Elizabeth K. Lee, Ursula A. Matulonis

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations mā Jennifer Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers mā Elizabeth K. Lee, David L. Kolin, Ursula A. Matulonis, Britt Erickson

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials mā Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies mā Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer mā S. Percy Ivy, Joyce F. Liu, Jung‐Min Lee, Ursula A. Matulonis, Elise C. Kohn

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines mā Brian J. Druker, Keiko Okuda, Ursula A. Matulonis, Ravi Salgia, Thomas M. Roberts, JD Griffin

    I whakaputaina 1992
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor mā Emily Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Karin Tyburski, Richard T. Penson, Benjamin D. Humphreys

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Ovarian cancer

    Ovarian cancer mā Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. mā Ursula A. Matulonis, Chrysoula Dosiou, GJ Freeman, Christine Lamont, Peter Mauch, L M Nadler, James D. Griffin

    I whakaputaina 1996
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma

    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma mā Elizabeth H. Stover, Colleen M. Feltmate, Ross S. Berkowitz, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health mā Alexi A. Wright, Nancy L. Keating, Tracy A. Balboni, Ursula A. Matulonis, Susan D. Block, Holly G. Prigerson

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study mā Melissa A. Merritt, Megan S. Rice, Mollie E. Barnard, Susan E. Hankinson, Ursula A. Matulonis, Elizabeth M. Poole, Shelley S. Tworoger

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks mā Kun‐Hsing Yu, Vincent J. Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine mā Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer

    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer mā Michelle Samora, José Eduardo Levi, Sergio Nicolau, Edvane De Domenico, Ursula A. Matulonis, Audrey Tieko Tsunoda, Pâmela Perez Leite, Rafael Schmerling

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance mā Raphaël Ceccaldi, Kevin W. O’Connor, Kent W. Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells mā Young Eun Choi, Chiara Battelli, Jacqueline Watson, Joyce F. Liu, Jennifer Curtis, Alexander Morse, Ursula A. Matulonis, Dipanjan Chowdhury, Panagiotis A. Konstantinopoulos

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: